ClinicalTrials.gg
CompletedNCT03302143Updated Oct 4, 2017

Radiographic and the Esthetic Outcome of Two Different Bone Grafting Techniques in Early Implant Placement

An interventional study of Guided bone regeneration with Bovine Bone Mineral and Guided bone regeneration with freeze dried bone allograft in Missing Tooth and Fractured Tooth, sponsored by The University of Texas Health Science Center at San Antonio. Completed. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-04.

Sponsored by The University of Texas Health Science Center at San Antonio · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 1 month after the study started (first participant enrolled Jul 2013, registered Sep 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Total of 48 subjects were randomly assigned to treatment groups:

UT Health Science Center at San Antonio Chi Mei Medical Center, Tainan, Taiwan

Patients require a maxillary non-molar extraction site that is planned to be replaced by a dental implant and crown. This includes Straumann BL SLActive: Narrow (3.3mm) \& Regular (4.1mm) Crossfit implants in all available lengths.

Patients were randomly selected to receive either FDBA (test) or Autogenous bone + DBBM (control/standard) for contour augmentation.

Read the detailed description

This comparative, randomized, prospective clinical study is designed to compare clinical outcomes and facial bone height and thickness of two different bone grafting techniques after augmentation in (Type 2) early implant placement.

Human subjects who could potentially qualify with the said inclusion criteria will be evaluated and screened. 24 human subjects who qualify for the procedure will have a thorough evaluation performed after obtaining consent from the patient. All subjects will require extraction of maxillary teeth (incisors, canines, premolars), followed by early implant placement of the missing teeth after 4 to 8 weeks extraction.

There will be two subject groups in this study in which the 24 human subjects in will randomly be placed by selecting the number "1" or "2" from a hat. 24 human subjects will be divided into two groups including 12 subjects using control group design and 12 subjects using test group design. 12 subjects will be placed randomly into Group 1 and will undergo the flapless extraction and early implant placement with GBR procedure using the control group design. 12 subjects will be placed randomly into Group 2 and will undergo the flapless extraction and early implant placement with GBR procedure using the test group design.

During the implant placement visit after 4 to 8 weeks of extraction, patient will be asked to select a number from a hat. If the number showed "1" as a control group, autograft , BBM and collagen membrane will be used as GBR materials after implant placement. If the number showed "2" as a test group, FDBA and collagen membrane will be used as GBR materials after implant placement.

Extraction sites will include maxillary teeth (11,12,13,14,15,21,22,23,24,25 according to FDI) having intact adjacent teeth. Implants placed for this study will have a SLActive surface, bone level design, Straumann NC 3.3mm or RC 4.1mm in diameter at all available implant lengths.

Control group: early implant placement with autograft plus BBM (Bio-Oss, Geistlich Pharm AG, Wolhausen, Switzerland) plus two layers of collagen membrane (BioGide®).

Test group: early implant placement with FDBA (Straumann Allograft GC®) plus two layers of collagen membrane (BioGide®).

These procedures will follow the guidelines as described by Buser et al. (2008). Implant placements will follow standard protocols utilizing tapping and placement with the hand ratchet.

A CBCT radiograph will be made during the screening visit to determine eligibility for the study and immediately following implant placement with GBR procedure to provide facial bone height and thickness measurements. The second CBCT procedure is not typically a standard of care procedure. After 12 months post loading healing time, the patient will receive another CBCT. This CBCT is also not a standard of care procedure but can accurately assess the amount of facial bone height and thickness maintained during the follow-up period.

02

Conditions studied

  • Missing Tooth
  • Fractured Tooth

Browse trials for

Keywords

  • Dental Implant
  • Guided Bone Regeneration
  • Contour Augmentation
03

In context

Tooth Fractures

37 studies on the registry are indexed under Tooth Fractures; 9 are open to participants now.

This study's enrollment of 48 is above the median of 40 across 33 interventional studies indexed under Tooth Fractures.

Browse Tooth Fractures studies →

Lead sponsor

The University of Texas Health Science Center at San Antonio is the lead sponsor of 445 studies on the registry; 89 are open to participants now.

Of its 65 completed or terminated interventional studies of FDA-regulated products, 35 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient is 18 years or older.
  2. Non-smoker or patient has smoking habit and \< 1 pack per day.
  3. Ability to understand and provide before starting the study.
  4. Ability and willingness to comply with all study requirements.
  5. The patient, if of , has a negative urine pregnancy test.
  6. Adequate oral hygiene to allow for implant therapy consistent with standards of care.
  7. Adequate primary stability following early implant placement protocols utilizing Straumann Bone Level implants NC 3.3mm or RC 4.1mm in diameter at all available implant lengths.
  8. One or more teeth in maxilla (11,12,13,14,15,21,22,23,24,25 according to FDI) has been identified as having a hopeless prognosis requiring extraction leading to a single-tooth gap requiring implant placement as determined by clinician.
  9. Implant site that has a defect and requires bone augmentation. This will be determined by measuring on the CBCT image the available space for the implant and whether or not there is enough bone width where the implant is to be placed.

Exclusion criteria

Exclusion Criteria:

  1. Patient reports current smoking habit > 1 pack per day or tobacco chewing use.
  2. History of alcoholism or drug abuse within the past 5 years.
  3. Severe bruxism or clenching habits.
  4. Patient has significant untreated periodontal disease (grade III or IV), caries, or clinical or radiographic signs of infection within two adjacent tooth positions of implant area.
  5. History of infection, or C.
  6. Patients with a history of systemic disease that precludes standard dental implant therapy.
  7. Presence of local inflammation or mucosal diseases such as lichen planus
  8. Patient history consistent with high risk for subacute bacterial endocarditis
  9. Current hematological disorder or coumadin (or similar) therapy
  10. Patient currently undergoing chemotherapy
  11. Patient history of radiation treatment to the head or neck
  12. Physical or mental handicaps that would interfere with patient's ability to exercise good oral hygiene on a regular basis
  13. Pregnant or breastfeeding women
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Active comparator
    Control

    Guided bone regeneration with Bovine Bone Mineral

    Procedure: Guided bone regeneration with Bovine Bone Mineral

  • Experimental
    Experimental

    Guided bone regeneration with freeze dried bone allograft

    Procedure: Guided bone regeneration with freeze dried bone allograft

Interventions

  • ProcedureGuided bone regeneration with Bovine Bone Mineral

    Guided bone regeneration with Bovine Bone Mineral

  • ProcedureGuided bone regeneration with freeze dried bone allograft

    Guided bone regeneration with freeze dried bone allograft

06

What researchers measure

Primary outcomes

  1. Facial bone thickness

    Facial bone thickness 1 year post-loading at 1, 3, and 5mm from the implant platform

    Time frame: Measured at 1 year post-loading

Secondary outcomes

  1. Change in facial bone thickness

    Change in facial bone thickness between implant placement and 1 year post-loading

    Time frame: Between implant placement and 1 year post-loading

  2. mPI measurement

    Measurement of modified Plaque Index

    Time frame: Measured at 6 and 12-months post-loading

  3. PD measurement

    Measurement of pocket depth

    Time frame: Measured at 6 and 12-months post-loading

  4. mSBI measurement

    Measurement of modified sulcus bleeding index

    Time frame: Measured at 6 and 12-months post-loading

  5. KM measurement

    Measurement of keratinized mucosa

    Time frame: Measured at 6 and 12-months post-loading

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2013 to primary completion in May 2016, 33 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2017
First posted
Oct 4, 2017
StartActual
Jul 30, 2013
Primary completionActual
May 15, 2016
CompletionActual
May 15, 2016
Last update
Oct 4, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03302143
Responsible party
Sponsor
First posted
Oct 4, 2017
Start date
Jul 30, 2013
Primary completion
May 15, 2016
Completion
May 15, 2016
Last update
Oct 4, 2017

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion